Minimally Invasive Blood Glucose Monitoring device Clinical Trial Analysis

Summary

Global Markets Direct's "Minimally Invasive Blood Glucose Monitoring device Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Minimally Invasive Blood Glucose Monitoring device manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

• The report provides analysis and review of the key clinical trials being carried out globally and across key Minimally Invasive Blood Glucose Monitoring device market categories - Minimally Invasive Blood Glucose Monitoring device
• The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
• The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
• The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

• Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
• Stay ahead of the information curve in the fast changing Minimally Invasive Blood Glucose Monitoring device market.
• Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
• Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

• 1 List of Tables
• 1.2 List of Figures
• 2 Minimally Invasive Blood Glucose Monitoring device Clinical Trials
  • 2.1 Minimally Invasive Blood Glucose Monitoring device Clinical Trial By Equipment Type
  • 2.2 Minimally Invasive Blood Glucose Monitoring device Clinical Trials By Trial Phase and Trial Status
  • 2.3 Minimally Invasive Blood Glucose Monitoring device Pipeline Products By Development Stage
  • 2.4 Minimally Invasive Blood Glucose Monitoring device Pipeline Products By Therapy Area
  • 2.5 Minimally Invasive Blood Glucose Monitoring device Pipeline Products By News Summary
  • 2.6 Minimally Invasive Blood Glucose Monitoring device GLUCOCARD X-METER GT-1910
    • 2.6.1 Evaluation Of Glucocard X-Meter Glucose Monitoring System
  • 2.7 Minimally Invasive Blood Glucose Monitoring device Glucoday
    • 2.7.1 Glucoday, A New Generation Subcutaneous Glucose Measuring
    • 2.7.2 Evaluation Of Different Techniques For Subcutaneous Glucose Monitoring In Type 1 Diabetic Patients During Real-Life Glucose Excursions
    • 2.7.3 No Apparent Local Effect Of Insulin On Interstitial Glucose Measurements
    • 2.7.4 Using The Glucoday System Proves Benefit In Patients With Poorly Controlled Type 2 Diabetes: A Randomized Multicenter Study
    • 2.7.5 The ID MAGIC (Interet En Diabetologie De La Mesure Ambulatoire Du Glucose Interstitiel En Continu) Study: The First French Survey On The Use Of Continuous Glucose Monitoring In Every Day Practice
    • 2.7.6 Hypo-Glycaemia Prevention Using CGM Time-Series: Relative Performance Of Different Prediction Methods
    • 2.7.7 Real Time Continuous Glucose Monitoring With Glucoday as an Assistant for Intensive Insulin Therapy in Diabetic Cardiothoracic Surgery Patients: a Randomized Study Comparing Blood Glucose Measurements Alone or Associated to Continue Glucose Monitoring
• 3 Recent Developments
  • 3.1 Product News
    • 3.1.1 Feb 09, 2009: ARKRAY Announces FDA Approval To Market GLUCOCARD 01-mini Blood Glucose Monitoring System
    • 3.1.2 Jul 23, 2008: BodyTel's Blood Glucose Monitoring And Diabetes Management System, GlucoTel, Passes TNO Tests
  • 3.2 Product Approvals
    • 3.2.1 Feb 09, 2009: ARKRAY Announces FDA Approval To Market GLUCOCARD 01-mini Blood Glucose Monitoring System
    • 3.2.2 Jul 23, 2008: BodyTel's Blood Glucose Monitoring And Diabetes Management System, GlucoTel, Passes TNO Tests
• 4 Appendix
  • 4.1 Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Expert Panel Validation
  • 4.2 Contact Us
  • 4.3 About Global Markets Direct
  • 4.4 Disclaimer
• 1 List of Tables
  • Table 1: Minimally Invasive Blood Glucose Monitoring device Clinical Trial By Equipment Type
  • Table 2: Minimally Invasive Blood Glucose Monitoring device Clinical Trials By Trial Phase and Trial Status
  • Table 3: Minimally Invasive Blood Glucose Monitoring device Pipeline Products By Development Stage
  • Table 4: Minimally Invasive Blood Glucose Monitoring device Pipeline Products By Therapy Area
  • Table 5: Minimally Invasive Blood Glucose Monitoring device Pipeline Products By News Summary
  • Table 6: GLUCOCARD X-METER GT-1910 - Evaluation Of Glucocard X-Meter Glucose Monitoring System
  • Table 7: Glucoday - Glucoday, A New Generation Subcutaneous Glucose Measuring
  • Table 8: Glucoday - Evaluation Of Different Techniques For Subcutaneous Glucose Monitoring In Type 1 Diabetic Patients During Real-Life Glucose Excursions
  • Table 9: Glucoday - No Apparent Local Effect Of Insulin On Interstitial Glucose Measurements
  • Table 10: Glucoday - Using The Glucoday System Proves Benefit In Patients With Poorly Controlled Type 2 Diabetes: A Randomized Multicenter Study
  • Table 11: Glucoday - The ID MAGIC (Interet En Diabetologie De La Mesure Ambulatoire Du Glucose Interstitiel En Continu) Study: The First French Survey On The Use Of Continuous Glucose Monitoring In Every Day Practice
  • Table 12: Glucoday - Hypo-Glycaemia Prevention Using CGM Time-Series: Relative Performance Of Different Prediction Methods
  • Table 13: Table 14: Glucoday - Real Time Continuous Glucose Monitoring With Glucoday as an Assistant for Intensive Insulin Therapy in Diabetic Cardiothoracic Surgery Patients: a Randomized Study Comparing Blood Glucose Measurements Alone or Associated to Continue Glucose Monitoring
• 1.2 List of Figures
  • Figure 1: Global Markets Direct Methodology